Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

Mergers & acquisitions

December 4, 2012: 10:39 AM ET

Byram Healthcare Systems, a White Plains, N.Y.-based subsidiary of Mediq NV, has acquired the medical supply unit of A-Med Health Care, a Huntington Beach, Calif.-based distributor of incontinence and urology supplies in the California market. No financial terms were disclosed. Intrepid Investment Bankers managed the process. www.byramhealthcare.com

Equifax Inc. (NYSE: EFX) has agreed to acquire the credit services group of Computer Sciences Corp.(NYSE: CSC). www.equifax.com

Salveo Specialty Pharmacy Inc., a St. Petersburg, Fla.-based specialty pharmacy organization, has acquired Los Angeles-based Mission Road Pharmacy for an undisclosed amount. In related news, Salveo has raised an undisclosed amount of new equity and debt funding from existing backers Three Arch Partners, NewSpring Capital and Petra Capital Partners, plus new backers Sofinnova Partners and Regions Bank. www.salveospecialty.com

Qualcomm Inc. (Nasdaq: QCOM) has agreed to invest $120 million into troubled Japanese electronics maker Sharp (Tokyo: 6753), as part of a broader strategic partnership. Qualcomm would hold around a 2.65% equity stake in Sharp. www.qualcomm.com

MML Capital Partners has sold MineTech International, a UK-based provider of land mine clearance and explosive ordnance disposal services, to Dynasafe Area Clearance Group. No financial terms were disclosed. Livingstone managed the sale process. www.minetech.co.uk

Nuance Communications
 has acquired Accentus, an Ontario-based provider of medical transcription, document imaging, and remote coding technology, from High Roads Capital Partners and BMO Capital Partners. No financial terms were disclosed, although High Road reports a 3.1x gross cash-on-cash return and a 49% gross IRR on the deal. www.accentus.com

Volcano Corp. (Nasdaq: VOLC) has agreed to acquire Crux Biomedical, a Menlo Park, Calif.–based developer of an inferior vena cava filter to treat pulmonary embolisms. The deal is valued at upwards of $39.1 million, including an up-front $36 million cash payment. Crux had raised around $27 million in VC funding from firms like Alloy VenturesEmergent Medical Partners and Three Arch Partnerswww.cruxbiomedical.com

Sign up for Dan's daily email newsletter on deals and deal-makers: GetTermSheet.com

Posted in:
Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.